Baqsimi (Glucagon) Patent Expiration, LOE Window & CMS Spending

Baqsimi (Glucagon) by Amphastar Pharmaceuticals: FDA Orange Book LOE 2039-09-23, 0 AB generics, $89.3M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAmphastar Pharmaceuticals
FDA Application & PathwayN210134 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2039-09-23
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$89.3M
2024 Medicare Part D Spend$21.5M
2024 Medicaid Spend$67.7M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel